Skip to main content
Fig. 4 | Arthritis Research & Therapy

Fig. 4

From: The trajectory of clinical responses in patients with early rheumatoid arthritis who achieve sustained remission in response to abatacept: subanalysis of AVERT-2, a randomized phase IIIb study

Fig. 4

DE-period SDAI categories in patients achieving sustained SDAI remission earlyb or laterc during the IP; intent-to-treat population. Unknown status refers to the patients for whom data were not available at that particular time point. SDAI categories: remission, ≤ 3.3; low disease activity, > 3.3–11; moderate disease activity, > 11–26; high disease activity, > 26. For parts A, B, and C, patients received SC abatacept QW + MTX during the IPd. For part D, patients received abatacept placebo + MTX during the IP and continued the same randomized treatment in the DE period. DE, de-escalation; EOW, every other week; IP, induction period; MTX, methotrexate; QW, once-weekly; SC, subcutaneous; SDAI, Simplified Disease Activity Index. aPart 1: abatacept EOW + MTX for 24 weeks; part 2: abatacept placebo + MTX for 24 weeks. bIP weeks 24, 40, and 52. cIP weeks 40 and 52, not 24. dOf the 56 patients from the abatacept + MTX arm who achieved sustained SDAI remission at weeks 24, 40, and 52 during the IP, SDAI status was unknown for four patients during the DE period of the study (data not shown)

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us